Dasatinib (for Ph+ ALL)
Treatment for Acute Lymphoid Leukemia
Typical Dosage: 100 mg orally once daily
Effectiveness
88%
Safety Score
55%
Clinical Trials
35
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
100 mg orally once daily
Time to Effect
4-8 weeks (for molecular response)
Treatment Duration
Long-term (years, often combined with chemotherapy)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$15,000
Side Effect Mgmt:$20,000
Total Annual:$185,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
1.8
Outcome-Based Costs
Cost per Responder
$205,556
Cost per Remission
$217,647
Comparison vs Imatinib + Chemotherapy
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Dasatinib (for Ph+ ALL) Outcomes
for Acute Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Myelosuppression
+70%
Fluid retention (pleural effusion)
+20%
Diarrhea
+30%
Headache
+20%
Rash
+15%
Active Clinical Trials
9 active trials recruiting for Dasatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394RECRUITINGPHASE2
74 participants
INTERVENTIONAL
Seoul, South Korea +5 more
Started: Oct 20, 2024
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882ACTIVE NOT RECRUITINGPHASE1
12 participants
INTERVENTIONAL
New York, United States
Started: Jun 29, 2015
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Chicago, United States
Started: Mar 2, 2021
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04329325ACTIVE NOT RECRUITINGPHASE2
17 participants
INTERVENTIONAL
New York, United States +1 more
Started: Mar 30, 2020
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
NCT06773936ENROLLING BY INVITATIONPHASE2
55 participants
INTERVENTIONAL
Cincinnati, United States +1 more
Started: Mar 15, 2026
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02143414ACTIVE NOT RECRUITINGPHASE2
53 participants
INTERVENTIONAL
Birmingham, United States +195 more
Started: Jun 30, 2015
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
NCT04996160RECRUITINGPHASE1
22 participants
INTERVENTIONAL
Stanford, United States
Started: Jul 9, 2021
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
NCT04872790RECRUITINGPHASE1
20 participants
INTERVENTIONAL
Portland, United States
Started: Sep 2, 2022
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041RECRUITINGPHASE3
150 participants
INTERVENTIONAL
Hefei, China +23 more
Started: Mar 28, 2025
Completed Clinical Trials
5 completed trials for Dasatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia
NCT02888990COMPLETEDPHASE2
71 participants
INTERVENTIONAL
Brussels, Belgium +63 more
Started: Aug 1, 2007
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
NCT02523976COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Tianjin, China
Started: Aug 1, 2015
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
NCT00940524COMPLETEDPHASE1
7 participants
INTERVENTIONAL
New York, United States
Started: Jul 1, 2009
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
NCT01004497COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Bucheon-si, South Korea +7 more
Started: Mar 1, 2010
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
NCT02081378COMPLETEDPHASE1
326 participants
INTERVENTIONAL
Boston, United States +17 more
Started: Apr 24, 2014
Showing 20 of 35 total trials